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ABSTRACT
Objective: In the present dissertation work, the aim was to prepare self-emulsifying drug delivery systems (SEDDS) of etoricoxib to improve its 
solubility with a view to enhance its oral bioavailability.
Methods: The prepared SEDDS was the concentrate of drug, oil, surfactants, and cosurfactant. The formulation was evaluated for various tests such as 
solubility, globule size, thermodynamic stability study, pH determination, ease of dispersibility, uniformity index, drug content, in-vitro release study, 
and in-vitro permeation study.
Results: The optimized formulation F6 showed drug release (79.21±2.73%), droplet size (0.546 µm). In vitro drug release of the F6 was highly 
significant (p<0.05) as compared to the plain drug.
Conclusion: All formulations of etoricoxib SEDDS were showed faster dissolution than plain drug (p<0.05), mean bioavailability of etoricoxib increase 
in respect to the plain drug. The F6 can be further used for the preparation of various solid SEDDS formulations.
Keywords: Dissolution, Self-emulsifying drug delivery systems, Solubility study, Bioavailability.
INTRODUCTION
Etoricoxib is a non-steroidal anti-inflammatory drug and has anti-
inflammatory, analgesic, and antipyretic activities. Etoricoxib is a 
selective cyclooxygenase 2 inhibitor, having anti-inflammatory and 
analgesic effects. It belongs to “BCS” class II and exhibits low & variable 
oral bioavailability due to its poor aqueous solubility. Etoricoxib 
absorption through oral route is dissolution rate limited, and so, it 
requires enhancement in solubility and dissolution rate for increasing 
its oral bioavailability [1,16-20].
Self-emulsifying drug delivery systems (SEDDS) is a potential tool for 
improving the bioavailability of drugs with poor aqueous solubility [2]. 
SEDDS is a basically isotropic mixture of drug, oil, surfactant, and 
cosurfactant. They spontaneously form emulsion on dilution with 
water with little or no energy input. Being hydrophobic, etoricoxib may 
be easily incorporated in the oily phase of SEDDS. On the basis of above-
mentioned criteria, it is wise to prepare SEDDS of etoricoxib [3,4].
In the present study, etoricoxib shall be formulated as SEDDS, and effect 
of different ratios of oil: smix (a mixture of surfactant and cosurfactant) 
in different concentrations was assessed on the release of etoricoxib.
METHODS
Etoricoxib was procured from Morepen Pvt. Ltd., Himachal Pradesh, 
as a gift sample. Soyabean oil (Ases Chemical Works, Jodhpur), Tween 
80 (Loba Chemie Pvt. Ltd., Mumbai), Span 80 (Loba Chemie Pvt. Ltd., 
Mumbai), glycerol (Siphon Laboratories, Jodhpur), methanol (Loba 
Chemie Pvt. Ltd., Mumbai), sodium lauryl sulfate (SLS) (S.D. Fine 
Chemical Ltd., Mumbai), ethanol (Siphon Laboratories, Jodhpur), 
dialysis membrane (Hi-Media, Mumbai), Whatman’s filter paper-42 
(Whatman Int. Ltd, England), deionized water (In-house laboratory), 
and other chemical and solvents were of analytical grade/IP/equivalent 
grade and procured from laboratory.
Formulation development of etoricoxib SEDDS
Solubility studies
The solubility of etoricoxib in various oils, surfactants, and cosurfactants 
was determined. 60 mg of drug was taken in test tube and fixed volume 
of oil/ surfactant/cosurfactant was added until the drug dissolved 
completely[5-7]. 
Construction of pseudo-ternary phase diagram
The pseudo-ternary phase diagram was constructed by water 
titration method using oil, surfactant 1, surfactant 2, cosurfactant, 
drug, and water. The mixtures of oil, surfactant 1, surfactant 2, and 
cosurfactant at certain weight ratios were diluted with water in a drop 
by drop manner. These diagrams were constructed to identify the 
self-emulsifying region and to optimize the concentration of oil. The 
pseudo-ternary phase diagram was constructed after normalization of 
readings by the aid of CHEMIX school 3_60 software. For every phase 
diagram, a specific ratio of surfactant 1: surfactant 2: cosurfactant 
(1:0.5:1, 1:1:1) was taken and  homogenous mixture of oil & drug was 
formed under the mixing by magnetic stirring. The various ratios of 
oil (containing drug):smix taken are 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 
8:2, 9:1, respectively. Then, every mixture was titrated with water 
and visually observed for flowability and phase clarity [8-11]. After 
the identification of a self-emulsifying region in the phase diagrams, 
the self-emulsifying formulations were selected at desired component 
ratios. The mixtures of selected surfactant and cosurfactant (Smix), 
i.e., Tween 80, Span 80, and glycerol were prepared in different ratios 
as presented in Table 1.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i7.18612
Research Article
368
Asian J Pharm Clin Res, Vol 10, Issue 7, 2017, 367-372
 Saurabh et al. 
Evaluation of etoricoxib SEDDS
Thermodynamic stability study of formulation
The following cycles are carried out for study:
Heating-cooling cycle
The prepared etoricoxib SEDDS (undiluted) were kept at a temperature 
between 40°C and 45°C and kept at a temperature between 4°C. This 
cycle is repeated 5 times [12-13].
Centrifugation
The prepared etoricoxib SEDDS (undiluted) were subjected to 
centrifugation at 3000 rpm for 30 minutes and observed visually for 
phase separation [14].
Freeze-thaw cycle
The prepared etoricoxib SEDDS (undiluted) were kept at a temperature 
between 0°C and 4°C and then allowed to melt at room temperature [15].
Homogeneity
The prepared SEDDS were inspected visually for their color and 
homogeneity [21-25].
pH determination
The pH of the prepared SEDDS pre-concentrates was determined by 
using a digital pH meter [12].
Optical transparency
The optical transparency of SEDDS formulations was determined by 
using nepheloturbidometer at nephelometric turbidity units 100 [27].
Globule size and shape
The globules of the prepared formulations were observed under 
a trinocular upright microscope, and the size of globules was 
determined [27].
Ease of dispersibility
The prepared mefenamic acid pre-concentrates are diluted (1 ml in 
100 ml) of water and then stirred on a magnetic stirrer at 50-100 rpm 
and visually observed for the ease of dispersibility and assigned 
following grades as shown in Table 2.
Uniformity index
Uniformity index is calculated to determine whether the prepared 
emulsion is monodispersed or polydispersed. It is the ratio of average 




























di=Mean diameter of particles; ni=Number of particles with diameter di.
If uniformity index is one, then the sample is monodispersed.
Drug content
5 ml of the prepared formulations were dissolved in 25 ml of methanol 
in volumetric flask, and volume was made up to 100 ml by methanol. 
The mixture is shaken well for 15-20 minutes and kept for 24 hrs. The 
solution was filtered through 0.45 µm Whatman filter paper. The filtrate 
was assayed spectrophotometrically at 232.5 nm using a ultraviolet 
(UV)-visible spectrophotometer [28,29].
In-vitro release study
This study was done to determine release behavior of formulation using 
dialysis technique. Dialysis membrane (Hi-media) of  pore size 2.4 nm 
and MWCO (Molecular weight cut-off) 12000-14000 was used for 
dissolution study. Before the diffusion studies, the dialysis membrane 
was soaked overnight in deionized water and for 1 hr in 1% SLS 
solution. The hydrated membrane was used for dissolution study. One 
end of the dialysis membrane/tubing was tied with a thread, and 1 ml of 
the SEDDS formulation and 1 ml of dialyzing medium (1% SLS solution) 
were filled in the membrane. The other end of the membrane is also 
tied with thread and then allowed to rotate in the dialyzing medium at 
50 rpm using USP dissolution apparatus II. Samples were withdrawn at 
different time intervals and then after suitable dilution were analyzed. 
The volume of samples withdrawn was replaced with the fresh dialyzing 
medium. The diffusion study was performed at 37±2°C to different 
time intervals for 2 hrs for formulated batch. Samples taken were then 
analyzed using UV spectrophotometer at 233.5 nm wavelength [30,31].
In vitro permeation study
Franz diffusion cell (with effective diffusion area 3.14 cm2 and 15 ml 
cell volume) was used for the drug release studies. Egg membrane was 
used for the release study. The egg membrane was obtained from hen’s 
egg (Gallus gallus; Genus: Gallus; Species: G. gallus) by keeping an egg 
in a 5 N HCl solution (200 ml). It was kept until the egg shell dissolved 
completely in HCl solution. Further, the egg was punctured, and egg yolk 
was discarded, and egg membrane was obtained, washed completely 
with de-ionized water and used.
Egg membrane was placed between donor and receptor compartments. 
In the receptor compartment of Franz diffusion cell, 1% SLS solution was 
filled, and 1 ml of SEDDS pre-concentrate with the same volume of 1% 
SLS solution was placed on the membrane through donor compartment. 
The release study was performed at 37±2°C to different time intervals for 
5 hrs for formulated batch. 1 ml of recipient fluid was withdrawn at time 
intervals as shown in Table 15 and replaced with equal volume of fresh 
medium. Samples were analyzed spectrophotometrically at 233.5 nm [31].
RESULTS AND DISCUSSION
The self-emulsifying formulations consisted of oil, surfactant, 
cosurfactant, and drug should be a clear and monophasic liquid at 
ambient temperature when introduced into an aqueous phase and 
Table 1: Ratios of Smix
S.No. Volume of surfactant 
1 (ml) (Tween 80)
Volume of surfactant 




Smix 1 30 15 30 1:0.5:1
Smix 2 30 30 30 1:1:1
Table 2: Grades for ease of dispersibility
S.No. Observation Grade
1. Rapidly forming nanoemulsion (bluish ) A
2. Rapidly forming microemulsion (blue to 
transparent) 
B
3. Fine milky emulsion formed in 2 min C
4. Dull oily emulsion formed in>2 min D
5. Poor or minimal emulsification with large oil 
globules on surface 
E
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should have good solvent properties to allow presentation of the drug 
in solution. The solubility of the drug in various vehicles is presented 
in Table 3.
Amongst oils, soyabean oil provided the highest solubility, then other 
and amongst surfactants Tween 80, Span 80 and amongst cosurfactants 
glycerol provided the highest solubility than other vehicles.
For the development of an SEDDS formulation, a right combination 
of low and high hydrophilic-lipophilic balance (HLB) surfactant is 
compulsory for the formulation of the stable microemulsion. Therefore, 
a high HLB surfactant (Tween 80) and low HLB surfactant (Span 80) 
were selected. Soyabean oil was found to be good with Tween 80 and 
Span 80; hence, it was selected for the optimal SEDDS formulation.
The pseudo-ternary phase diagram of the system comprising the 
surfactant 1, surfactant 2, cosurfactant, and the oily phase was 
constructed for Smix 1 and Smix 2 and is shown in Figs. 1 and 2. Pink 
area represents the region of self-emulsification. Within this area, a 
ternary mixture converts into fine oil in water emulsion with only 
gentle agitation. This is possible as the surfactant strongly localized 
to the surface of the emulsion droplet reduces interfacial free energy 
and provides a strong mechanical barrier to coalescence resulting 
in a thermodynamically spontaneous dispersion. Furthermore, 
cosurfactants increase interfacial fluidity by penetrating into the 
surfactant film creating void space among surfactant molecules.
On the basis of pseudo-ternary phase diagram study, following formulas 
have been derived from the area of the pseudo-ternary diagram for the 
two ratios 1:0.25:1 (F1, F2, F3), 1:1:1 (F4, F5, F6). The formulation 
composition of the etoricoxib SEDDS is presented in Table 4.
It has been found that none of the prepared etoricoxib SEDDS 
(undiluted) showed phase separation after subject to heating-cooling, 
centrifugation, and freeze-thaw cycling. The observations for phase 
separation after heating-cooling cycle, centrifugation, and freeze-
thawing are shown in Tables 5-7, respectively.
Fig. 1: Pseudoternary phase diagram for water:soyabean oil 
containing 100 mg mefenamic acid:smix 1 (Smix 1 - Tween 
80:Span 80:Glycerol - 1:0.5:1)
Fig. 2: Pseudoternary phase diagram for water:soyabean oil 
containing 100 mg mefenamic acid:smix 2 (Smix 2 - Tween 
80:Span 80:glycerol - 1:1:1)
Fig. 3: Etoricoxib self-emulsifying drug delivery system
Table 3: Solubility of etoricoxib in various vehicles
S.No. Oil Volume of 
vehicle (ml)
Parts of vehicle 
required to dissolve 
1 part of etoricoxib
1. Isopropyl myristate 1 16.66
2. Castor oil 1 16.66
3. Soyabean oil 1 16.66
4. Oleic acid 1 16.66
5. Olive oil 1 16.66
6. Sunflower oil 1 16.66
7. Groundnut oil 1 16.66
8. Sesame oil 1 16.66
9. Octanol 1 16.66
10. Tween 80 1 16.66
11. Span 80 2 33.33
12. Tween 20 1 16.66
13. Span 20 2 33.33
14. Polyethylene glycol 1 16.66
15. Propylene glycol 2 33.33










F1 300 6.25 18.75 -
F2 300 5 20 -
F3 300 4.16 20.84 -
F4 300 6.25 - 18.75
F5 300 5 - 20
F6 300 4.16 - 20.84
SEDDS: Self-emulsifying drug delivery system
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All SEDDS formulations were of yellow color, viscous preparation with 
an oily and homogeneous appearance as shown in Fig. 3. 
The pH of all the pre-concentrates F1 to F6 was found to be in the range 
of 7.1-7.5, which lies in the normal pH range of the physiological fluids 
and would not produce any irritation, which is shown in Table 8.
The results show that the transmittance for F1, F2, F3, F4, F5, and F6 is 
87.33±2.08, 91±2, 81.66±4.04, 98.33±0.57, 90.66±0.57, and 90.33±0.57, 
respectively, from which it can be inferred that F4, F5, and F6 are most 
transparent and it was due to low globule size of o/w emulsion which 
forms after dilution with water. The readings were taken in triplicate, 
and the average was calculated as shown in Table 9.
The formulation F4 was found to contain smallest mean globule size, 
whereas there is a slight increase in mean globule size of formulations 
F5 and F6. Furthermore, the globule size of F1 is largest. The mean 
globule size was calculated as shown in Table 10, and the optical 
microgram is presented in Fig. 4.
On the basis of the visual observations, it has been found that all the 
formulations of Smix 1 and Smix 2 are of B grade (Table 11), i.e., they 
rapidly form a transparent microemulsion.
Table 5: Observations for phase separation (heating-cooling cycle)




Duration (minutes) Number of cycles Observations for phase 
separation
1. F1 40-45 4 30 5 No
2. F2 40-45 4 30 5 No
3. F3 40-45 4 30 5 No
4. F4 40-45 4 30 5 No
5. F5 40-45 4 30 5 No
6. F6 40-45 4 30 5 No
Table 6: Observations for phase separation (after centrifugation)
S.No. Formulation code rpm Duration (min) Observations
1. F1 2000-3000 30 No phase separation
2. F2 2000-3000 30 No phase separation
3. F3 2000-3000 30 No phase separation
4. F4 2000-3000 30 No phase separation
5. F5 2000-3000 30 No phase separation
6. F6 2000-3000 30 No phase separation
Table 7: Observations for phase separation (after freeze-thaw cycling)
S.No. Formulation code Freezing 
temperature (°C)
Thawing temperature Duration (hrs) Number of cycles Observations
1. F1 0 Room temperature 18 1 No phase separation
2. F2 0 Room temperature 18 1 No phase separation
3. F3 0 Room temperature 18 1 No phase separation
4. F4 0 Room temperature 18 1 No phase separation
5. F5 0 Room temperature 18 1 No phase separation
6. F6 0 Room temperature 18 1 No phase separation
Table 8: Determined pH of etoricoxib SEDDS







*Data indicate mean±SD (n=3). SD: Standard deviation, SEDDS: Self-emulsifying 
drug delivery system
Table 9: Transmittance of etoricoxib SEDDS







*Data indicate mean±SD (n=3). SEDDS: Self-emulsifying drug delivery system
Table 10: Mean globule size of prepared formulations







Table 11: Observations for ease of dispersibility
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The uniformity index of F1, F2, F4, and F5 formulations found to be near 
1 to 2; hence, these formulations can be considered as monodispersed. 
The observations of uniformity index are shown in Table 12.
The percentage content was found to range between 87.14±6.24% and 
105.36±5.08% which is within the acceptable range of 100±15% which 
indicated the homogeneous distribution of drug throughout the SEDDS. 
The observations of drug content are shown in Table 13.
The release of etoricoxib from Smix 1 (F1, F2, F3) formulations is quite 
low as compared to all the formulations of Smix 2 (F4, F5, F6). The 
reason accountable for the above observation is the small mean globule 
size of Smix 2 formulations as compared to Smix 1. Hence, it can be 
inferred that decreasing the globule size of the drug can increase the 
release of the drug and it might suggest that release rate of the drug 
can be controlled by regulating the mean globule size. Furthermore, it 
has been found that the release of etoricoxib is high in case of all the 
formulations (F1 to F6) as compared to the plain drug. All formulations 
of etoricoxib SEDDS were showed faster dissolution than plain drug 
Fig. 4: Optical micrograph of etoricoxib self-emulsifying drug 
delivery system at ×40 magnification





























F1 1.597782 1.514184397 1.055209774
F2 1.49916069 1.481854839 1.011678506
F3 1.912771619 1.330508475 1.437624529
F4 1.053475936 0.54389313 1.936917159
F5 1.235 0.593155894 2.082083333
F6 1.069724771 0.546747967 1.956522629
Table 13: Drug content of the prepared etoricoxib SEDDS







Data indicate mean±SD (n=5). SD: Standard deviation, SEDDS: Self-emulsifying 
drug delivery system
Table 14: In-vitro release of etoricoxib from prepared SEDDS pre-concentrates
%Cumulative drug release±SD
Time (minutes) F1 F2 F3 F4 F5 F6 Plain drug
0 0 0 0 0 0 0 0
5 3.14±2.15 2.42±2.11 10.07±0.74 9.96±6.71 9.50±5.51 15.21±4.13 0.58±2.51
15 8.25±6.80 7.32±7.61 9.50±5.51 23.07±3.77 22.53±8.32 38.60±6.55 1.03±5.71
30 26.32±8.60 25.60±5.30 22.53±8.32 40.21±2.67 35.28±6.41 58.71±4.85 2.84±4.33
45 31.67±4.71 30.53±5.36 35.28±6.41 59.14±4.77 44.64±9.43 68.67±2.002 4.15±7.12
60 47.64±6.52 45.32±8.81 44.64±9.43 65.85±2.72 59.28±10.21 72.17±5.86 8.96±2.01
120 51.42±5.66 51.78±5.49 59.28±10.21 72.17±5.86 70.85±13.48 79.21±2.73 10.51±1.29
Data indicate mean±SD (n=3). SD: Standard deviation, SEDDS: Self-emulsifying drug delivery system
Table 15: In vitro release of etoricoxib through egg membrane
% In vitro release of etoricoxib through egg membrane±SD
Time (min) F1 F2 F3 F4 F5 F6 Plain drug
0 0 0 0 0 0 0 0
30 0.92±1.24 3.28±1.92 3.30±2.06 4.0±2.710 1.07±1.07 5.42±2.14 0
60 4.46±2.73 5.75±0.59 7.07±1.40 5.92±1.03 4.82±2.15 7.0±0.97 0
120 9.07±3.90 16.39±0.32 16.28±5.57 14.31±3.07 14.6±4.10 13.25±3.76 0
180 17.67±2.10 17.46±1.51 27.67±3.97 32.71±2.76 20.46±5.47 32.0±1.6 0
240 22.42±2.01 30.42±2.78 41.75±3.38 40.82±3.49 29.10±2.64 39.39±1.64 0
300 27.39±1.66 34.75±7.62 43.53±1.45 50.39±6.55 40.89±3.02 53.964±10.13 0
*Data indicate mean±SD (n=3). SD: Standard deviation 
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(p<0.05). However, F6 formulation of Smix 2 showed best performance 
(%R120: 79.21±2.73) in enhancing solubility and dissolution rate 
of etoricoxib suggesting an optimum ratio of oil and Smix. The 
observations of dissolution study are shown in Table 14.
The release of the etoricoxib from all etoricoxib SEDDS formulations 
was observed, and the SEDDS formulation can be ranked in the 
following descending order: F6 > F4 > F3 > F5 > F2 > F1 where the 
amounts of the etoricoxib released after 5 hrs were 53.964±10.13, 
50.39±6.55, 43.53±1.45, 40.89±3.02, 34.75±7.62, and 27.39±1.66, 
respectively. At the 5th hr, the higher drug release was observed with 
formulation F6. The reason accountable for the above observation is 
the small mean globule size F6 formulations as compared to all other 
formulations. The observations of in vitro release study are shown in 
Table 15. All formulations of etoricoxib SEDDS were showed faster 
dissolution than plain drug (p<0.05), mean bioavailability of etoricoxib 
increase in respect to the plain drug.
CONCLUSION
A SEDDS formulation of a poor water soluble drug, etoricoxib was 
formulated for oral administration. The formulation F6 was found to 
be the optimized formulation on the basis of results of pseudo-ternary 
phase diagram, dissolution study, in vitro drug release, droplet size. The 
optimized formulation showed rapid self-emulsification in aqueous 
media. In vitro drug release of the F6 was highly significant (p<0.05) 
as compared to the plain drug. The results from the study show the 
utility of SEDDS to enhance solubility and dissolution of sparingly 
soluble compounds such as etoricoxib. The F6 can be further used for 
the preparation of various solid SEDDS formulations.
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